C.M. Pilard , L. Gassiat , C. Cardouat , I. Gauthereau , P. Robillard , E. Dumas-de-la-Roque , F. Sauvestre , F. Pelluard , S. Berenguer , L. Sentilhes , F. Coatleven , M. Vincienne , R. Marthan , P. Berger , V. Freund-Michel , C. Guibert
{"title":"Is the Cx43-specific inhibitor 43Gap26 a relevant therapeutic target in BPD and BPD-PH induced by hyperoxia?","authors":"C.M. Pilard , L. Gassiat , C. Cardouat , I. Gauthereau , P. Robillard , E. Dumas-de-la-Roque , F. Sauvestre , F. Pelluard , S. Berenguer , L. Sentilhes , F. Coatleven , M. Vincienne , R. Marthan , P. Berger , V. Freund-Michel , C. Guibert","doi":"10.1016/j.rmr.2025.02.080","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Premature newborns exposed to oxygen are at risk for bronchopulmonary dysplasia (BPD), characterized by lung growth arrest and inflammation. Connexin 43-gap junction (Cx43-GJ) plays a central role in lung development and macrophages-induced inflammation, and is increased by hyperoxia. We thus explored the role of CX43-GJ in experimental BPD.</div></div><div><h3>Methods</h3><div>We used neonatal rats exposed to normoxia or hyperoxia (90% O<sub>2</sub>) and daily treated or not with a specific Cx43 inhibitor (43Gap26) during 14 days. Some experiments were also performed in human fetal pulmonary artery smooth muscle cells (HfPA-SMC) exposed to normoxia or hyperoxia (60% O<sub>2</sub>) and treated or not with 43Gap26 for 2 days.</div></div><div><h3>Results</h3><div>In vivo, we showed that 43Gap26 decreased hyperoxia-induced increased Cx43 expression in lung and improved hypo-alveolarization. However, 43Gap26 did not prevent 1) the hyperoxia-induced alteration of lung function (plethysmographie), 2) the decreased SP-B expression, 3) the disruption of extracellular matrix components (fibronectin and collagen I/III), 4) the increased macrophagic infiltration and M2 polarization, and 5) the increased secretion of pro-inflammatory cytokines (Tissue Inhibitor of Metalloproteinases-1). Furthermore, 43Gap26 blocked the hyperoxia-induced proliferation of type II alveolar epithelial cells, and did not prevent BPD-associated pulmonary hypertension (PH-BPD) or the increased mortality. In vitro, on HfPA-SMC, we confirmed that although an increased Cx43 expression was induced by hyperoxia, 43Gap26 had no effect on the hyperoxia-induced increase of pro-inflammatory cytokines such as IL-6 and Macrophage Inhibitory Factor (MIF). Finally, although we did not demonstrate an increase in oxidative stress in our 2 models, 43Gap26 decreased the hyperoxia-induced increase in heme oxygenase-1 expression in pulmonary arteries.</div></div><div><h3>Conclusion</h3><div>Despite an improved alveolarization in an animal model of hyperoxia-induced BPD, specific inhibition of Cx43 does not appear to be a new potential therapeutic strategy in BPD and PH-BPD as it did not prevent mortality as well as the main hallmarks of BPD and PH-BPD (altered lung function, pulmonary vascular growth arrest and remodeling, inflammation).</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 221"},"PeriodicalIF":0.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue des maladies respiratoires","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0761842525001238","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Premature newborns exposed to oxygen are at risk for bronchopulmonary dysplasia (BPD), characterized by lung growth arrest and inflammation. Connexin 43-gap junction (Cx43-GJ) plays a central role in lung development and macrophages-induced inflammation, and is increased by hyperoxia. We thus explored the role of CX43-GJ in experimental BPD.
Methods
We used neonatal rats exposed to normoxia or hyperoxia (90% O2) and daily treated or not with a specific Cx43 inhibitor (43Gap26) during 14 days. Some experiments were also performed in human fetal pulmonary artery smooth muscle cells (HfPA-SMC) exposed to normoxia or hyperoxia (60% O2) and treated or not with 43Gap26 for 2 days.
Results
In vivo, we showed that 43Gap26 decreased hyperoxia-induced increased Cx43 expression in lung and improved hypo-alveolarization. However, 43Gap26 did not prevent 1) the hyperoxia-induced alteration of lung function (plethysmographie), 2) the decreased SP-B expression, 3) the disruption of extracellular matrix components (fibronectin and collagen I/III), 4) the increased macrophagic infiltration and M2 polarization, and 5) the increased secretion of pro-inflammatory cytokines (Tissue Inhibitor of Metalloproteinases-1). Furthermore, 43Gap26 blocked the hyperoxia-induced proliferation of type II alveolar epithelial cells, and did not prevent BPD-associated pulmonary hypertension (PH-BPD) or the increased mortality. In vitro, on HfPA-SMC, we confirmed that although an increased Cx43 expression was induced by hyperoxia, 43Gap26 had no effect on the hyperoxia-induced increase of pro-inflammatory cytokines such as IL-6 and Macrophage Inhibitory Factor (MIF). Finally, although we did not demonstrate an increase in oxidative stress in our 2 models, 43Gap26 decreased the hyperoxia-induced increase in heme oxygenase-1 expression in pulmonary arteries.
Conclusion
Despite an improved alveolarization in an animal model of hyperoxia-induced BPD, specific inhibition of Cx43 does not appear to be a new potential therapeutic strategy in BPD and PH-BPD as it did not prevent mortality as well as the main hallmarks of BPD and PH-BPD (altered lung function, pulmonary vascular growth arrest and remodeling, inflammation).
期刊介绍:
La Revue des Maladies Respiratoires est l''organe officiel d''expression scientifique de la Société de Pneumologie de Langue Française (SPLF). Il s''agit d''un média professionnel francophone, à vocation internationale et accessible ici.
La Revue des Maladies Respiratoires est un outil de formation professionnelle post-universitaire pour l''ensemble de la communauté pneumologique francophone. Elle publie sur son site différentes variétés d''articles scientifiques concernant la Pneumologie :
- Editoriaux,
- Articles originaux,
- Revues générales,
- Articles de synthèses,
- Recommandations d''experts et textes de consensus,
- Séries thématiques,
- Cas cliniques,
- Articles « images et diagnostics »,
- Fiches techniques,
- Lettres à la rédaction.